The problem
An incorrect picture of 'mRNA' COVID-19 vaccines being more effective than 'viral vector' COVID-19 vaccines was forming across APAC.
We readied to overcome a threat to vaccine trust
Earlier this year, Vaxzevria, AstraZeneca's 'viral vector' COVID-19 vaccine, was battling perception issues, with stakeholders holding the misconception that mRNA COVID-19 vaccines were more effective in preventing the virus' most serious outcomes, hospitalisation and death.
What in part fed this misconception, was regular announcements regarding the amount of antibodies that 'mRNA' COVID-19 vaccines could initially trigger, rather than a focus on the key job of the vaccine, long-term...